AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25457929
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management plus instructions in cognitive-behavioral therapy (CBT)
Trial: 28412602
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management plus full CBT
Trial: 22955172
Drug: Lenalidomide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (single doses of 5-400 mg)
Trial: 12435003
Drug: Various disinfecting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various disinfecting solutions
Trial: 12435003
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no disinfecting solution)
Trial: 9987734
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) with hMG/hCG and DIPI
Trial: 6853264
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) administered orally at a dose of 3.0g/m2 and intravesically at a dose of 1.0g
Trial: 22260826
Drug: Immune-enhancing enteral
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-enhancing enteral solution (group II)
Trial: 22260826
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral solution (group III)
Trial: 22260826
Drug: Parenteral solution
RxNorm normalized name: Triferic, 27.2 mg/5 mL parenteral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral solution (group IV)
Trial: 20605499
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d soy isoflavones
Trial: 20605499
Drug: 120 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/d soy isoflavones
Trial: 18653341
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline infusion
Trial: 8950072
Drug: LDL apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL apheresis treatment
Trial: 1757613
Drug: Halobetasol propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol propionate 0.05% cream
Trial: 6753643
Drug: Midazolam, 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, 0.07 mg/kg (group M, 31 patients)
Trial: 6753643
Drug: Hydroxyzine, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 1.0 mg/kg (group H, 34 patients)
Trial: 29583015
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day resveratrol
Trial: 24120713
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 100 μg FPNS
Trial: 24120713
Drug: 1 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 × 400 μg FPNS
Trial: 24120713
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 100 μg FPNS
Trial: 24120713
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 100 μg FPNS and 1 × 400 μg FPNS
Trial: 21283921
Drug: Imiquimod 3.75%
RxNorm normalized name: IMIQUIMOD 3.75% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 3.75% cream (two-week cycle)
Trial: 21283921
Drug: Imiquimod 2.5%
RxNorm normalized name: IMIQUIMOD 2.5% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 2.5% cream (two-week cycle)
Trial: 21283921
Drug: Imiquimod 3.75%
RxNorm normalized name: IMIQUIMOD 3.75% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 3.75% cream (three-week cycle)
Trial: 21283921
Drug: Imiquimod 2.5%
RxNorm normalized name: IMIQUIMOD 2.5% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 2.5% cream (three-week cycle)
Trial: 19042940
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (500 mg)
Trial: 12636956
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream
Trial: 18001442
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal suppositories
Trial: 11581566
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training regimens differing in dose (kcal.wk‐1) and/or intensity (relative to peak VO2)
Trial: 2340210
Drug: Verapamil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (40 mg)
Trial: 7404209
Drug: Low-dose intramuscular
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intramuscular ketamine and hyaluronidase
Trial: 31915163
Drug: Single-dose cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose cephalosporin
Trial: 19291119
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of 75 microg of Heberprot‐P three times per week up to complete wound healing
Trial: 17522570
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg) followed by intravenous NTG (up to 80 microg/min)
Trial: 17522570
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by intravenous NTG (up to 160 microg/min)
Trial: 11788176
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (continuous conjugated equine estrogens (CEE) ‐ 0.625mg per day)
Trial: 11788176
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy (patches delivering continuous 17beta‐estradiol (E2)‐‐0.05mg per day)
Trial: 11788176
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral CEE and transdermal E2)
Trial: 29151313
Drug: 10 physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 physical therapy sessions (Group 10)
Trial: 29151313
Drug: 15 physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 physical therapy sessions (Group 15)
Trial: 9014954
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) during rehabilitation
Trial: 8302446
Drug: Ventilated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilated with O2 = 350 ml/min‐1 and N2O = 250 ml/min‐1, reducing N2O flow to keep FIO2 = 0.4
Trial: 26980389
Drug: Nasal douches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal douches based on high concentration (9 mg) and high-molecular-weight sodium hyaluronate (active treatment group)
Trial: 26980389
Drug: Nasal saline
RxNorm normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal saline solution irrigation (control group)
Trial: 15917152
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone extract with PUFA supplement (two capsules per day for 24 weeks)
Trial: 15917152
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules per day for 12 weeks)
Trial: 12650788
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy (OBMT) with omeprazole, bismuth biskalcitrate 140 mg, metronidazole 125 mg, and tetracycline 125 mg for 10 days.
Trial: 12650788
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (OAC) with omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg for 10 days.
Trial: 8646868
Drug: Hydrocortisone-17-butyrate ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone-17-butyrate ointment, 0.1%
Trial: 6373152
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg oxaprozin once daily
Trial: 6373152
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg naproxen 3-times daily
Trial: 22251483
Drug: Cytokine-based immunotherapy
RxNorm normalized name: Cytokine-based biologic agent IRX-2
DrugBank: IRX-2 (DB05643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine-based immunotherapy
Trial: 22251483
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied immunomodulatory treatment
Trial: 20705755
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction and consolidation therapy
Trial: 17620446
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min exercise starting 120 min after dosing (EX120)
Trial: 17620446
Drug: 30 min
RxNorm normalized name: Goddess Garden SPF 30 Mineral Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min exercise starting 240 min after dosing (EX240)
Trial: 16332666
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (2.5 mg) plus vitamin B‐12 (500 microg)
Trial: 16332666
Drug: Vitamin B‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B‐6 (25 mg)
Trial: 16332666
Drug: Riboflavin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (25 mg)
Trial: 8583673
Drug: Bromazepam suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam suppository
Trial: 2476520
Drug: Aclatonium (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclatonium (300 mg)
Trial: 30694377
Drug: MRI through
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI through intravenous gadolinium administration (IV-Gd)
Trial: 26124497
Drug: Intensified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified therapy for MRD >0.1%
Trial: 17914032
Drug: metformin (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (2,000 mg)
Trial: 15280105
Drug: L-arginine 3
RxNorm normalized name: Natrol Men's Health L-Arginine 3,000mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine 3 g daily orally for 20 days
Trial: 11762418
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (e.g., Rituxan, Mylotarg, Campath)
Trial: 11762418
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies as monotherapy or in combination with conventional chemotherapies
Trial: 11762418
Drug: Engineered antibodies
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engineered antibodies
Trial: 11762418
Drug: Antibody engineering
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody engineering
Trial: 7829762
Drug: brofaromine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brofaromine 150 mg daily (n = 111)
Trial: 7829762
Drug: brofaromine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brofaromine 150 mg daily
Trial: 27998964
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg daily plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Trial: 27998964
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Trial: 26165360
Drug: Continuous 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 3.0 intradermal non-absorbable polypropylene suture (Prolene™ 0, Ethicon Inc. Somerville, New Jersey, USA)
Trial: 23715754
Drug: GFT505 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFT505 (80 mg/day)
Trial: 16574037
Drug: P‐ERMS once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐ERMS once daily in AM or PM for a 4‐week treatment period
Trial: 9402690
Drug: CsA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA with MMF (1.0 g bid)
Trial: 9402690
Drug: CsA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA with MMF (1.5 g bid)
Trial: 29638148
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg IV infusion twice daily for up to 14 days
Trial: 29638148
Drug: Cimetidine 50
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 50 mg/h continuous IV infusion following an initial bolus of 300 mg for up to 14 days
Trial: 30182671
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Levocetirizine and Montelukast
Trial: 23535873
Drug: Beta-alanine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (6.4 g · d(‐1) for 4 weeks)
Trial: 20495586
Drug: Cervical interlaminar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical interlaminar epidural injections with 0.5% lidocaine (4 mL) mixed with 1 mL of non-particulate betamethasone
Trial: 15985032
Drug: Ciclopirox 0.77%
RxNorm normalized name: CICLOPIROX 0.77% SUSP,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox 0.77% gel applied twice daily
Trial: 15985032
Drug: Ciclopirox 0.77%
RxNorm normalized name: CICLOPIROX 0.77% SUSP,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopirox 0.77% gel applied once daily
Trial: 12325402
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (two 40‐min sessions per week for 5 weeks)
Trial: 7795096
Drug: TMP-SMZ (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMZ (640 mg/3,200 mg)
Trial: 2343070
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg haloperidol
Trial: 7000476
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg chenodeoxycholic acid (CDC)/day
Trial: 7000476
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg chenodeoxycholic acid (CDC)/day
Trial: 7000476
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg CDC/day (after 6 months for placebo patients)
Trial: 26180108
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose target of 100‐140 mg/dL (n = 151)
Trial: 26180108
Drug: Conservative glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative glucose target of 141‐180 mg/dL (n = 151)
Trial: 24375220
Drug: Oral Targin
RxNorm normalized name: naloxone hydrochloride / oxycodone hydrochloride Extended Release Oral Tablet [Targiniq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Targin (oxycodone-hydrochloride and naloxone hydrochloride-dihydrate)
Trial: 24375220
Drug: Patient-controlled IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled IV morphine
Trial: 19900154
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Exercise and Pravastatin
Trial: 10636271
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy for acute myocardial infarction (AMI)
Trial: 8731641
Drug: Sodium picosulphate
RxNorm normalized name: Sodium Picosulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium picosulphate solution (Picolax)
Trial: 8731641
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol bowel lavage solution (Klean Prep)
Trial: 1413580
Drug: Drugs and
RxNorm normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs and graded walking
Trial: 1413580
Drug: Drugs and
RxNorm normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs and low-effort bicycle exercise
Trial: 4054193
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of original lipophilic beta-blocker
Trial: 26795423
Drug: General practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practitioner (GP) treatment as usual
Trial: 24697877
Drug: L-NMMA (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (during atorvastatin and placebo treatment)
Trial: 22332798
Drug: Metformin (achieved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (achieved glycemic control with HbA1c ≤ 8% for at least 2 months)
Trial: 20009090
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day rimonabant
Trial: 12795771
Drug: Alefacept 7.5
RxNorm normalized name: ALEFACEPT 7.5MG/VI INJ KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 7.5 mg IV
Trial: 12795771
Drug: Alefacept 7.5
RxNorm normalized name: ALEFACEPT 7.5MG/VI INJ KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept 7.5 mg IV (after second course)
Trial: 10596705
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone (500 microg b.i.d., for three weeks)
Trial: 10596705
Drug: Nonsteroid medication
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid medication (control group)
Trial: 8739860
Drug: Oxy- and
RxNorm normalized name: Pur-Oxy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy- and xylometazoline nasal sprays
Trial: 8739860
Drug: Topical vasoconstrictors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vasoconstrictors
Trial: 8739860
Drug: Benzalkonium chloride
RxNorm normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzalkonium chloride in nasal decongestant solutions
Trial: 1924660
Drug: Venlafaxine 25
RxNorm normalized name: venlafaxine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 25 mg t.i.d.
Trial: 1924660
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg t.i.d.
Trial: 1924660
Drug: Venlafaxine 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 125 mg t.i.d.
Trial: 29426270
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (EvPO) 1000 mg, twice daily for 7 days
Trial: 25450583
Drug: 100mg/day coQ10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg/day coQ10 capsules
Trial: 22189825
Drug: Antiglaucomatous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiglaucomatous therapy (various medications including metipranolol 0.3%, timolol 0.5%, dorzolamid, brinzolamid, brimonidine, bimatoprost, travoprost, and latanoprost)
Trial: 22189825
Drug: Monotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy and dual therapy (two substances in one drug)
Trial: 22189825
Drug: Prostaglandin agonists
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin agonists (PGA)
Trial: 22189825
Drug: Timolol plus
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol plus brinzolamide (combined therapy)
Trial: 20211296
Drug: Enteric-coated aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin, 100 mg/d
Trial: 10368815
Drug: Flaxseed (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (5 g/day)
Trial: 10368815
Drug: Flaxseed (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (10 g/day)
Trial: 8768018
Drug: Mixed parenteral
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed parenteral and enteral nutrition
Trial: 7045615
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy plus BCG
Trial: 7045615
Drug: PPD conversion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD conversion from negative to positive during therapy
Trial: 19460609
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration before CABG